
BLS Pharmaceuticals has rapidly transformed into a profitable regulated-medicines manufacturer, supported by strong revenue growth, controlled-substance licences and international expansion. While FY26 guidance remains ambitious, bearish RSI divergence suggests traders should monitor key support levels closely.